Search Results
Your search for them matches 6128 pages
Showing 1351 - 1400Managing Long-Term Toxicity From Pelvic Radiation Therapy
Advances over the past 3 decades in improvements in cancer prevention and screening strategies and more effective diagnostics and therapies in cancer care have led to unprecedented declines in death rates from all cancers, including prostate, gynecologic, and colorectal/anal cancers. The fastest...
The Road to a Career in Breast Oncology Took Several Twists and Turns for Sara A. Hurvitz, MD, FACP
Breast cancer specialist Sara A. Hurvitz, MD, FACP, grew up in the East Bay area of Northern California, the youngest of five children. “My mother was a traditional stay-at-home mom, and my father was a probation officer. I come from a long line of artists; my great-grandfather on my mother’s side...
ABC Sixth International Consensus Conference Updates Guidelines for Advanced Breast Cancer
New recommendations for treating advanced breast cancer, coming from a panel of experts at the Advanced Breast Cancer (ABC) Sixth International Consensus Conference (ABC6), were recently published.1 The report highlights advances that have resulted in robust improvements in overall survival for...
Expert Point of View: Mikkael A. Sekeres, MD
Mikkael A. Sekeres, MD, Professor of Medicine and Chief of the Division of Hematology, Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine, said the “fascinating” findings of the study reported by Bouzid et al make it worthy of an ASH Plenary Session...
Combinations Advance the Power of Pembrolizumab in Hodgkin Lymphoma
Pembrolizumab monotherapy is an established treatment strategy for relapsed or refractory classical Hodgkin lymphoma. In combination with chemotherapy, the checkpoint inhibitor is also showing value in the front-line setting and further boosting outcomes in the relapsed setting, according to...
Grieving the Loss of Sexual Intimacy as a Result of Cancer and Its Treatment
About 5 years ago, I began experiencing some digestive issues that I initially blamed on the stress from coping with my mother’s diagnosis of Alzheimer’s disease. But after 2 weeks of unrelenting symptoms, including abdominal pain, a change in my bowel habits, and rectal bleeding, I saw my primary...
Study Identifies Factors Impacting Adherence to Oral Medications for Metastatic Breast Cancer
A recent study published by Conley et al in Breast Cancer Research and Treatment aimed to evaluate factors that influence the ability of people with metastatic breast cancer to adhere to their prescribed regimen of oral anticancer medication.1 Researchers found that multiple factors affected...
Cancer in the Arab World: Addressing Challenges to Improve Outcomes
I returned home to the United Arab Emirates in 2017, following my oncology fellowship training and work experience in the United States. I immediately realized that I am now dealing with a considerably different cancer patient population in terms of age of onset, stage at presentation, awareness...
From a Low-Income Family in Puerto Rico, to a Leadership Role in Oncology for Gerardo Colón-Otero, MD
In this installment of Living a Full Life, guest editor Jame Abraham, MD, spoke with Gerardo Colón-Otero, MD, Professor of Medicine at Mayo Clinic College of Medicine, Past Chair of the Division of Hematology/Oncology at the Mayo Clinic in Florida, and Vice Dean at Mayo Clinic Alix School of...
Emerging Issues Regarding Artificial Intelligence in Cancer Research and Clinical Practice
Artificial intelligence (AI) has captured society’s imagination and generated enthusiasm for its potential to improve our quality of life, especially in the health-care arena. The availability of high-dimensionality data sets along with innovations in high-performance computing and deep-learning...
Massage for Pain Management in the Cancer Population
Guest Editor’s Note: Pain is a debilitating symptom experienced by many patients with cancer that negatively impacts their quality of life. Massage therapy, historically used for relaxation and pain relief, plays an important supportive role in oncology settings. In this installment of The ASCO...
Robust and Durable Responses to Pembrolizumab in Patients With Previously Treated MSI-H/dMMR Endometrial Cancer
“Robust and clinically meaningfulantitumor activity,” with durable responses and “encouraging survival outcomes,” were reported among patients with previously treated microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) endometrial tumors who received pembrolizumab in the...
Research Outlines Obstetric and Perinatal Outcomes for Female Survivors of Childhood Cancer
Survivors of childhood cancer who become pregnant in adulthood are as likely to have healthy babies as those without a history of cancer, according to a new study published by Zgardau et al in the Journal of the National Cancer Institute. Their children also don’t have higher risks of birth defects ...
Study Finds World Trade Center First Responders Have High Burden of Clonal Hematopoiesis
Scientists have determined that first responders to the World Trade Center during the September 11, 2001, terrorist attacks have increased levels of mutations that may escalate their risk for blood cancers or cardiovascular disease, according to a study published by Jasra et al in Nature Medicine....
President’s Cancer Panel Report: Closing Gaps in Cancer Screening for All Americans
Much progress has been made in the past 50 years since the signing of the National Cancer Act of 1971, which included the establishment of the President’s Cancer Panel. Nevertheless, there remain significant opportunities to make improvements across the cancer spectrum, perhaps none more pressing...
Linda Fleisher, PhD, MPH, Appointed Co-Chair of American Cancer Society’s National Navigation Roundtable
Linda Fleisher, PhD, MPH, Associate Research Professor in the Cancer Prevention and Control research program at Fox Chase Cancer Center, was recently appointed Co-Chair of the American Cancer Society’s National Navigation Roundtable. Patient navigators act as intermediaries between patients and...
Humanitarian Paul Farmer, MD, PhD, Dies at 62
"One of the great advocates for the poorest and sickest of our planet.” —Nobel Peace Prize laureate Archbishop Desmond Tutu “Our mission is to provide a preferential option for the poor in health care. By establishing long-term relationships with sister organizations ...
PADA-1 Trial: With Early Identification of ESR1 Mutation, Switch to Fulvestrant in Metastatic Breast Cancer
Switching from an aromatase inhibitor to fulvestrant upon early identification of the ESR1 mutation in plasma—before disease progression—doubled progression-free survival in the phase III PADA-1 trial, presented at the 2021 San Antonio Breast Cancer Symposium.1 “PADA-1 is the first trial to...
Final Analysis of PALLAS Trial: No Benefit of Adjuvant Palbociclib Plus Endocrine Therapy in Early Breast Cancer
The final protocol-defined analysis of the phase III PALLAS trial confirmed the negative results of the second interim analysis, showing no benefit of palbociclib plus endocrine therapy in the adjuvant breast cancer setting. Michael Gnant, MD, of the Medical University of Vienna, reported these...
RxPONDER Update Explores Benefit of Chemotherapy in Subgroups
Updated results of the SWOG S1007 RxPONDER trial confirmed the key takeaway from the previous analysis: adjuvant chemotherapy benefits premenopausal women but not postmenopausal women with hormone receptor–positive, HER2-negative disease, one to three positive lymph nodes, and a 21-gene Oncotype DX ...
Expert Point of View: Angela DeMichele, MD, MSCE
Angela DeMichele, MD, MSCE, the Alan and Jill Miller Professor in Breast Cancer Excellence at the Perelman School of Medicine of the University of Pennsylvania in Philadelphia, commented on NIMBUS1 for The ASCO Post. She said obtaining information on tumor mutational burden is simple, as it is...
Expert Point of View: Hope S. Rugo, MD, FASCO
The discussant of KEYNOTE-522 at the 2021 San Antonio Breast Cancer Symposium, Hope S. Rugo, MD, FASCO, Professor of Medicine and Director of Breast Oncology and Clinical Trials Education at the University of California San Francisco Comprehensive Cancer Center, commented: “We are clearly making...
Highlights From the 2021 San Antonio Breast Cancer Symposium
In its first return to a hybrid model since the COVID-19 pandemic began, the 2021 San Antonio Breast Cancer Symposium (SABCS) brought together researchers, clinicians, industry experts, patients, and advocates from across the globe to present and grapple with new data and important topics in breast ...
Long-Term Rates of Hospital Readmission for Venous Thromboembolism After Complex Cancer Surgery
In a U.S. retrospective cohort study reported in JAMA Surgery, Mallick et al found that hospital readmission for venous thromboembolism events (VTEs) continued beyond 30 days after complex cancer surgery. As stated by the investigators: “…VTE is a major cause of preventable morbidity and mortality...
FDA Approves FoundationOne CDx as a Companion Diagnostic for Pembrolizumab to Identify Patients With MSI-H Solid Tumors
On February 21, the U.S. Food and Drug Administration (FDA) approved FoundationOne CDx to be used as a companion diagnostic to identify patients with microsatellite instability–high (MSI-H) status solid tumors who may be appropriate candidates for treatment with pembrolizumab. FoundationOne CDx is...
Expert Point of View: Philip L. McCarthy, MD
The ASCO Post invited myeloma expert Philip L. McCarthy, MD, Director of the Transplant and Cellular Therapy Program at Roswell Park Comprehensive Cancer Center, Buffalo, New York, to comment on the trials evaluating early detection of myeloma at the 2021 American Society of Hematology (ASH) Annual ...
ZUMA-7: Axicabtagene Ciloleucel Quadruples Event-Free Survival in Large B-Cell Lymphoma
In the primary analysis of the phase III ZUMA-7 trial, examining second-line therapy for relapsed or refractory large B-cell lymphoma, the CAR T-cell therapy axicabtagene ciloleucel led to a fourfold increase in event-free survival over the standard of care. These findings were presented at the...
Expert Point of View: Jane N. Winter, MD, and Christopher R. Flowers, MD, MS
Jane N. Winter, MD, Professor of Medicine at Northwestern University’s Feinberg School of Medicine and 2022 President of the American Society of Hematology (ASH), and Christopher R. Flowers, MD, MS, Chair of the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center,...
Why Some Patients With Cancer Are Reluctant to Receive COVID-19 Vaccination: Survey Shows Need to Improve Patient-Physician Communication
“My doctor has not told me to get the vaccine.” That was the number one reason patients with cancer gave in a survey at an outpatient infusion therapy clinic for not having received at least one dose of the COVID-19 vaccine. Rivalling that reason were concerns about safety and fear of vaccine side...
As a Black Woman, I Knew I Had to Advocate for the Best Breast Cancer Care
When I got the call from the radiology department telling me I had to come back for a follow-up mammogram right before Christmas of 2020, I wasn’t surprised or initially concerned. I have dense breasts, and my first mammogram 2 years earlier had also detected suspicious areas in one of my breasts...
Reflecting on the Past 50 Years of Cancer Progress and Looking Ahead to the Next 50 Years of Advances
In December 2021, Nobel laureates, cancer center directors, physicians, scientists, politicians, public health officials, and patient advocates gathered at the Richard Nixon Presidential Library and Museum in Yorba Linda, California, to celebrate the 50th anniversary of the signing of the National...
ASTRO Issues Clinical Guideline on External-Beam Radiation Therapy for Primary Liver Cancers
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of external-beam radiation therapy (EBRT) to treat adults with primary liver cancers. The guideline, ASTRO’s first for primary liver cancers, is published in Practical Radiation ...
Single-Cell Spatial Connectivity Analysis Offers ‘Unprecedented’ Information in Breast Cancer
A next-generation technology that focuses on protein expression at the single-cell level has yielded a wealth of information about “spatial connectivity” between cancer cells and their microenvironment. It also provided information on the benefit of adding the immune checkpoint inhibitor...
Expert Point of View: Susan M. O’Brien, MD
The GAIA trial raises some important points, according to Susan M. O’Brien, MD, Associate Director for Clinical Research at the UCI Chao Family Comprehensive Cancer Center in Irvine, California. Dr. O’Brien co-moderated the session where Dr. Eichhorst presented study results. “The CLL14 trial...
In Case You Missed It: Brief Highlights From the 2021 ASH Annual Meeting & Exposition
COVID has upended our world, and medical conferences have had to adapt to ever-shifting sands depending on the behavior of the variants of the virus that emerge. The 2021 American Society of Hematology (ASH) Annual Meeting & Exposition was no exception, offering a hybrid meeting for in-person...
Expert Point of View: Rona Yaeger, MD
Rona Yaeger, MD, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, New York, discussed the results of the GALAXY trial,1 first putting them into context with previous studies. As she pointed out, the finding of an 11-fold increase in risk of recurrence in patients who...
Understanding How LGBTQI+ Cancer Survivors Experience Cancer Care
Members of the lesbian, gay, bisexual, transgender, and queer/questioning, intersexed (LGBTQI+) community face numerous challenges and barriers when accessing the health-care system in the United States, including cancer care; as a result, they may be at greater risk for developing cancer and...
BELINDA: CAR T-Cell Therapy Fails to Improve Outcomes in Aggressive Non-Hodgkin Lymphoma
The autologous chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel failed to improve event-free survival vs standard-of-care treatment strategies in patients with aggressive, relapsed or refractory non-Hodgkin lymphoma (NHL), according to the results of the phase III BELINDA trial,...
Study Evaluates Effectiveness of Existing Risk Stratification System for Hepatoblastoma
A new study published by Zhou et al in JAMA Network Open independently verified the value of a system that assesses hepatoblastoma risk in children. The researchers also discovered the potential for tumor histology to predict a patient’s hepatoblastoma prognosis. Hepatoblastoma is a rare childhood ...
Expert Point of View: Joshua Brody, MD
Joshua Brody, MD, Director of the CLL/Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai, New York, who was not involved in these trials, commented: “CLL is an extremely prevalent disease affecting nearly 200,000 patients in the United States. Most patient do not require...
Expert Point of View: Susan M. O’Brien, MD
The GAIA trial raises some important points, according to Susan M. O’Brien, MD, Associate Director for Clinical Research at the UCI Chao Family Comprehensive Cancer Center in Irvine, California. Dr. O’Brien co-moderated the session where Dr. Eichhorst presented study results. “The CLL14 trial...
Expert Point of View: Mikkael A. Sekeres, MD
Mikkael A. Sekeres, MD, Professor of Medicine and Chief of the Division of Hematology, Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine, said the “fascinating” findings of the study reported by Bouzid et al make it worthy of an ASH Plenary Session...
Centralizing Care for Adolescents and Young Adults With Cancer to Improve Long-Term Survivorship
This past fall, Memorial Sloan Kettering (MSK) Cancer Center in New York expanded its adolescent and young adult (AYA) program with the establishment of the Lisa and Scott Stuart Center for Adolescent and Young Adult Cancers. The Stuart Center is now part of the increasing list of about 50 academic ...
Studies Show That Laws to Limit Opioid Prescribing Have Hampered Pain Control for Patients With Cancer
In 2015, an unprecedented phenomenon occurred in the United States: according to the World Bank Group, the nation’s average life expectancy fell from 78.8 years in 2014 to 78.7 years in 2015, then to 78.5 years in 2017. The last time our life expectancy registered a similar decline was in the years ...
Are Patients Undergoing Active Cancer Treatment More Likely to Believe COVID-19 Misinformation?
Patients with cancer undergoing active treatment were more likely to believe misinformation related to COVID-19 than those without a history of cancer, according to a new study published by Guidry et al in Patient Education and Counseling. “These findings help us better understand the threat of...
Study Identifies Factors Impacting Adherence to Oral Medications for Metastatic Breast Cancer
A recent study published by Conley et al in Breast Cancer Research and Treatment aimed to evaluate factors that influence the ability of people with metastatic breast cancer to adhere to their prescribed regimen of oral anticancer medication. Researchers found that multiple factors affected...
Study Finds Patients With Lung Cancer Demonstrated Psychological Resilience in the Face of the COVID-19 Pandemic
Far from being hobbled by fears of COVID-19, patients with lung cancer actually showed less depression and anxiety during the pandemic than their healthy peers, according to results from a new study by Arrato et al published in JNCCN–Journal of the National Comprehensive Cancer Network. Researchers ...
Jaye Gardiner, PhD, Receives Inaugural Black in Cancer Postdoctoral Fellowship for Pancreatic Cancer Research
Jaye Gardiner, PhD, a postdoctoral researcher at Fox Chase Cancer Center, has received an inaugural Black in Cancer postdoctoral fellowship, which is funded by Emerald Foundation Inc. Dr. Gardiner will receive $75,000 annually for 3 years, which will fund her research into pancreatic ductal...
Expert Point of View: Angela DeMichele, MD, MSCE
Angela DeMichele, MD, MSCE, the Alan and Jill Miller Professor in Breast Cancer Excellence at the Perelman School of Medicine of the University of Pennsylvania in Philadelphia, commented on NIMBUS1 for The ASCO Post. She said obtaining information on tumor mutational burden is simple, as it is part ...
Expert Point of View: Hope S. Rugo, MD, FASCO
The discussant of KEYNOTE-522 at the 2021 San Antonio Breast Cancer Symposium, Hope S. Rugo, MD, FASCO, Professor of Medicine and Director of Breast Oncology and Clinical Trials Education at the University of California San Francisco Comprehensive Cancer Center, commented: “We are clearly making...
